Blood test guides new attack on lung cancer return
NCT ID NCT04585477
First seen Feb 11, 2026 · Last updated May 01, 2026 · Updated 14 times
Summary
This study is for people with early-stage non-small cell lung cancer who have finished standard treatment. A blood test looks for tiny bits of cancer DNA (ctDNA) that might mean the cancer could come back. If the test is positive, participants get a drug called durvalumab to try to clear that DNA and lower the risk of the cancer returning. The study will check if the drug works by seeing if the DNA levels drop.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.